Rheumatoid arthritis "vaccine" passes big test

 
Related

Rescued bear, lion and tiger "brothers" refuse to be separated after 15 years together

Puyol Mos
708 points

Human Trials For A Vaccine That Destroys Cancerous Tumors Just Began

Puyol Mos
532 points



Most recent

Johnson Controls fortalece la seguridad del sector bancario en América Latina

TECH2022
44 points

Modelos de Cat phones acumulan 49 premios en 10 años

Comms1
32 points

LAS BOTAS ALTAS DE CAUCHO SON EL PEOR ENEMIGO DE LOS CAMPESINOS

Image Press
12 points

Un virólogo del CSIC vaticina cada cuánto tiempo habrá que vacunarse contra el Covid-19

NOTICIAS-ETF
234 points

DistroTV eleva su oferta de canales a más de 270

Comms1
14 points

Hablamos de COVID-19 y sus variantes: El riesgo de muerte se triplica en los pacientes no vacunados

NOTICIAS-ETF
136 points

Hallan en la Antártida superbacterias capaces de generar nuevas enfermedades

NOTICIAS-ETF
22 points

Colombianos diversifican inversiones, ante escenarios económicos y sociopolíticos adversos

Image Press
40 points

Fernando Simón explica por qué se dispararán los contagios de Covid este verano

NOTICIAS-ETF
60 points

Simplemente Gracias, la nueva apuesta de LOS TRI-O por la música romántica

TECH2022
26 points
SHARE
TWEET
Scientists have created a vaccine-style therapeutic approach to treat rheumatoid arthritis.

Rheumatoid arthritis "vaccine" passes big test

Results from the phase one clinical trial, published in Science Translational Medicine, demonstrate the new treatment is safe and effective in suppressing the immune response, says Professor Ranjeny Thomas of the University of Queensland Diamantina Institute.

Rheumatoid arthritis is a disease in which the immune system attacks healthy tissues, particularly in the joints, causing inflammation, pain, and deformity.

Thomas says the treatment targeted the underlying cause of rheumatoid arthritis. “Current therapies only treat the symptoms and slow the progression of the disease,” says Thomas.

TEACHING THE IMMUNE SYSTEM
“We have designed a vaccine-style treatment or ‘immunotherapy’ specifically for individuals carrying high-risk rheumatoid arthritis genes and specific rheumatoid arthritis antibodies, called anti-CCP. This type of rheumatoid arthritis is called ‘CCP-positive’ and accounts for the majority of cases.

“Our immune system is made up of specialized cells that move through blood and tissue, preventing disease and fighting infection by distinguishing between what is the body’s own healthy tissue and what is foreign,” she explains.

“This treatment teaches the patient’s immune system to ignore a naturally occurring peptide that is incorrectly identified as ‘foreign,’ resulting in the production of CCP antibodies and causing inflammation.

“A personalized immunotherapy was prepared for each patient by taking a sample of their blood and extracting a particular type of immune cell called dendritic cells,” says Thomas. “The patient’s dendritic cells were then challenged with the ‘foreign’ peptide and an immune system modulator. The treated dendritic cells were then injected back into the patient.”

Thomas says a single injection of the patient’s own immune-modified dendritic cells was found to be safe and to help suppress the immune response in rheumatoid arthritis. “This in turn was associated with reduced inflammation,” she says.

NEXT STEPS
“At this stage, the technique would not be ideal for widespread treatment or prevention of rheumatoid arthritis because it’s costly and time-consuming,” adds Thomas.

“However, the promising results of this trial lay the foundations for the development of a more cost-effective, clinically-practical vaccine technology that could deliver similar outcomes for patients.

Professor Thomas is working on a delivery technology with Dendright Pty Ltd (a UniQuest start-up company) in collaboration Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

If the delivery of this technology proves successful in patients with rheumatoid arthritis, it could also be applied to other autoimmune diseases such as type 1 diabetes.

Fuente: www.futurity.org
SHARE
TWEET
To comment you must log in with your account or sign up!

Comentarios más recientes
Crystal Peters
you make $27h...good for you! I make up to $85h working from home. My story is that I quit working at shoprite to work online and with a little effort I easily bring in around $45h to $85h heres a good example of what I'm doing BEST PROFIT DEAL \ CHECK ,,,, WWW.PROFIT-REVIEW.COM
 
Featured content